Trials / Completed
CompletedNCT02864407
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
A Regulatory Required Non Interventional Study to Monitor the Safety and Effectiveness of Once Daily Treatment of Orally Inhaled Vahelva Respimat (Tiotropium + Olodaterol Fixed Dose Combination 2.5µg/2.5µg Per Puff (2 Puffs Comprise One Medicinal Dose)) for Korean Patients With COPD (Chronic Obstructive Pulmonary Disease)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,223 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
Detailed description
Study Design: regulatory PMS study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) | The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day. |
Timeline
- Start date
- 2016-12-19
- Primary completion
- 2021-01-20
- Completion
- 2021-01-20
- First posted
- 2016-08-12
- Last updated
- 2022-03-28
- Results posted
- 2022-01-19
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02864407. Inclusion in this directory is not an endorsement.